Autolus Therapeutics (AUTL) Long-Term Deferred Tax (2019 - 2025)

Autolus Therapeutics (AUTL) has reported Long-Term Deferred Tax for 7 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 9.91% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 9.91% YoY) and the FY2025 annual result came in at $3.6 million, up 9.91% from the prior year.
• Long-Term Deferred Tax grew to $3.6 million in Q4 2025 per AUTL's latest filing, from $2.4 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for AUTL reached as high as $3.6 million in Q4 2025 and fell as low as $1.4 million in Q3 2021.
• A 5-year average of $2.5 million and a median of $2.4 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2021 — Long-Term Deferred Tax soared 396.1% — and 2025, when it dropped 29.51%.
• Year by year, Long-Term Deferred Tax stood at $1.8 million in 2021, then grew by 13.69% to $2.1 million in 2022, then jumped by 47.54% to $3.1 million in 2023, then advanced by 5.75% to $3.2 million in 2024, then gained by 9.91% to $3.6 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $3.6 million, $2.4 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.